drugset / Trial / NCT06122493
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study aims to investigate a comprehensive therapeutic approach for patients with unresectable esophageal squamous cell carcinoma, clinically staged as Tany, N3, M0, and who are not candidate for concurrent chemoradiotherapy combined with immunotherapy. The approach entails combining chemotherapy with immune therapy, followed by synchronized radiotherapy during the immune maintenance phase. The primary goal is to mitigate treatment-related side effects and enhance the overall prognosis through the integration of these treatment modalities.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Subject | Tirelizumab | Monoclonal antibody | 200 mg | — |